Cemiplimab Considerably Improved Overall Survival in Patients With Advanced NSCLC 
Recently, the manufacturers of the fully human monoclonal antibody cemiplimab halted the phase lll trial for this agent because of promising results demonstrating that the use of this agent in combination with chemotherapy for first-line, advanced non–small cell lung cancer (NSCLC) improved overall survival. Read more.

Lung Cancer Screening Rates Mostly Unchanged During Pandemic
At the beginning of the COVID-19 pandemic, in March 2020, routine screenings for cancer were paused and the impact on lung cancer screenings was unknown. In a recent publication, researchers examined annual lung cancer screening rates before (2019) and during the pandemic nationally and according to state. Read more.

FDA Grants Priority Review to Atezolizumab for Early Non-Small Cell Lung Cancer
On August 2, 2021, the FDA granted Priority Review for the agent atezolizumab for the treatment of early non–small cell lung cancer. The agent, marketed as Tecentriq, is the first and only cancer immunotherapy to demonstrate positive phase III results in the adjuvant lung cancer setting. Read more.